The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.
 
Amy Sanders Clark
Honoraria - Siemens
Consulting or Advisory Role - Novartis
Research Funding - Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Fengmin Zhao
Employment - Forma Therapeutics Inc (I)
 
Paula Klein
No Relationships to Disclose
 
Alberto J. Montero
Honoraria - AstraZeneca; Celgene; OncoSec
Consulting or Advisory Role - New Century Health; Paragon healthcare; Welwaze
(OPTIONAL) Uncompensated Relationships - Roche
 
Carla Isadora Falkson
Honoraria - Curio Science
Consulting or Advisory Role - Agendia; bioTheranostics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Lilly (Inst); Oncolytics (Inst); QuantumLeap Health (Inst)
 
Elisa Krill-Jackson
No Relationships to Disclose
 
Kendrith M. Rowland
No Relationships to Disclose
 
Sagar D. Sardesai
No Relationships to Disclose
 
Jason Anthony Incorvati
Consulting or Advisory Role - 2nd.MD
 
Patrick Michael Dillon
Research Funding - Daichi Sankyo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Tolero Pharmaceuticals (Inst)
 
Antonio C. Wolff
Research Funding - Array BioPharma (Inst); Genentech (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Houra Loghmani
Employment - Oncolytics; Oncolytics
Stock and Other Ownership Interests - Oncolytics
 
Richard Trauger
No Relationships to Disclose
 
Thomas Charles Heineman
Employment - Oncolytics
Leadership - Oncolytics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Halozyme; Johnson & Johnson/Janssen; Oncolytics; Pfizer; Takeda
Consulting or Advisory Role - Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - Halozyme: PCT/US19/32537 Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble PH20 Genocea: PCT/US 62/855,309; PCT/US 62/848,527 Methods of identifying and/or selecting antigens that improve, increase and/or s
Travel, Accommodations, Expenses - Oncolytics
 
Matthew C. Coffey
Employment - Oncolytics
Leadership - Oncolytics
Stock and Other Ownership Interests - Oncolytics
Patents, Royalties, Other Intellectual Property - Oncolytics
 
Kathy Miller
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Celcuity; Genentech/Roche; Merck
Research Funding - alphamab (Inst); Astex Pharmaceuticals (Inst); British Biotech (Inst); CytomX Therapeutics (Inst); Pfizer (Inst)